29th April 2022
Series A funding round will help IMPLICITY accelerate international expansion and fuel AI-based medical algorithm development.
IMPLICITY®, a leader in remote patient monitoring and cardiac data management solutions, announced yesterday that it has raised €21 million in Series A funding led by new investors: Crédit Mutuel Innovation and Bpifrance.
IMPLICITY’s European development was supported by EIT Health via the Bridgehead Europe programme, in which the start-up participated in 2020. Interim Business Creation Lead, Héloïse Priou, stated: “We are glad to hear that IMPLICITY is developing its presence on new international markets. Thanks to this fundraising, IMPLICITY will be able to further accelerate its international expansion”.
According to Dr. Arnaud Rosier, CEO and founder of IMPLICITY, “this financing round marks a new and exciting chapter for IMPLICITY. With clinical staff everywhere wrestling with an increasing volume of data coming from the growing number of connected devices, the need for a universal remote platform is now widely recognised as paramount. Coverage of remote care sparked by Covid-19 set the scene. In order to democratise remote cardiac care, our mission is to provide healthcare professionals with the best technology available to scale and monitor all cardiac patients”.
The new funding will help speed the international rollout of IMPLICITY’s AI-based technology and cardiac data management solutions — enabling healthcare professionals around the world with a more holistic approach to caring for cardiac patients. Proceeds will be used to:
- Increase the company’s market presence in the US and support expansion into new markets
- Develop additional medical device software to strengthen the technological leadership of the company